AstraZeneca PLC - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
AZN Nasdaq 2830 www.astrazeneca.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for AstraZeneca PLC

Why Is AstraZeneca PLC (AZN) Among the Best Large-Cap Value Stocks to Buy in 2025? - Jan 22nd, 2025 8:47 pm
AstraZeneca gains NICE nod for lung cancer drugs Tagrisso and Imfinzi - Jan 22nd, 2025 5:48 pm
FDA Approves AstraZeneca's Datroway For Pretreated Breast Cancer Patients - Jan 21st, 2025 5:54 pm
J&J’s Lazcluze/Rybrevant combination obtains European approval to treat NSCLC - Jan 21st, 2025 4:57 pm
AstraZeneca Secures FDA Nod for New ADC Drug Datroway in Breast Cancer - Jan 20th, 2025 7:05 pm
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick - Jan 20th, 2025 2:50 pm
FDA Approves Two Breakthrough Cancer Treatments for AstraZeneca - Jan 20th, 2025 2:20 pm
AstraZeneca secures first BTK approval in first-line mantle cell lymphoma - Jan 20th, 2025 12:54 pm
Trending tickers: Trump Media, Intel, Alibaba, Novo Nordisk and Entain - Jan 20th, 2025 11:24 am
Tariff threats, drug pricing will be 2 key pharma issues during Trump's first year - Jan 18th, 2025 5:31 pm
Ozempic, Xtandi among next 15 drugs selected for U.S. price talks - Jan 18th, 2025 1:20 pm
DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer - Jan 17th, 2025 10:35 pm
Medicare to negotiate prices on 15 drugs, including Ozempic - Jan 17th, 2025 9:13 pm
Pharma Stock Roundup: J&J's ITCI Buyout, LLY's Weak Q4 Sales - Jan 17th, 2025 8:00 pm
Novo Nordisk's stock down 4% as the Feds get ready for a second round of drug price negotiations - Jan 17th, 2025 2:46 pm
AstraZeneca overhauls management of its scandal-hit China division - Jan 17th, 2025 1:32 pm
CALQUENCE® (acalabrutinib) plus chemoimmunotherapy approved in the US for patients with previously untreated mantle cell lymphoma - Jan 17th, 2025 12:00 pm
COPD market to expand with AstraZeneca’s focus on biologics and strong portfolio growth - Jan 17th, 2025 11:42 am
JP Morgan 2025: AstraZeneca promises a ‘catalyst-rich’ year ahead - Jan 15th, 2025 7:57 pm
3 High-Yielding Dividend Stocks That Are Trading at Dirt Cheap Prices - Jan 15th, 2025 9:58 am